1
|
Li J, Wu Y, Xiang J, Wang H, Zhuang Q, Wei T, Cao Z, Gu Q, Liu Z, Peng R. Fluoroalkane modified cationic polymers for personalized mRNA cancer vaccines. CHEMICAL ENGINEERING JOURNAL (LAUSANNE, SWITZERLAND : 1996) 2023; 456:140930. [PMID: 36531858 PMCID: PMC9743697 DOI: 10.1016/j.cej.2022.140930] [Citation(s) in RCA: 32] [Impact Index Per Article: 16.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 09/01/2022] [Revised: 11/12/2022] [Accepted: 12/10/2022] [Indexed: 06/17/2023]
Abstract
Messenger RNA (mRNA) vaccines, while demonstrating great successes in the fight against COVID-19, have been extensively studied in other areas such as personalized cancer immunotherapy based on tumor neoantigens. In addition to the design of mRNA sequences and modifications, the delivery carriers are also critical in the development of mRNA vaccines. In this work, we synthesized fluoroalkane-grafted polyethylenimine (F-PEI) for mRNA delivery. Such F-PEI could promote intracellular delivery of mRNA and activate the Toll-like receptor 4 (TLR4)-mediated signaling pathway. The nanovaccine formed by self-assembly of F-PEI and the tumor antigen-encoding mRNA, without additional adjuvants, could induce the maturation of dendritic cells (DCs) and trigger efficient antigen presentation, thereby eliciting anti-tumor immune responses. Using the mRNA encoding the model antigen ovalbumin (mRNAOVA), our F-PEI-based mRNAOVA cancer vaccine could delay the growth of established B16-OVA melanoma. When combined with immune checkpoint blockade therapy, the F-PEI-based MC38 neoantigen mRNA cancer vaccine was able to suppress established MC38 colon cancer and prevent tumor reoccurrence. Our work presents a new tool for mRNA delivery, promising not only for personalized cancer vaccines but also for other mRNA-based immunotherapies.
Collapse
Affiliation(s)
- Junyan Li
- Institute of Functional Nano & Soft Materials (FUNSOM), Soochow University, 199 Ren'ai Rd, Suzhou, Jiangsu 215123, China
- Jiangsu Key Laboratory for Carbon-Based Functional Materials and Devices, Soochow University, 199 Ren'ai Rd, Suzhou, Jiangsu 215123, China
| | - Yuanyuan Wu
- Institute of Functional Nano & Soft Materials (FUNSOM), Soochow University, 199 Ren'ai Rd, Suzhou, Jiangsu 215123, China
- Jiangsu Key Laboratory for Carbon-Based Functional Materials and Devices, Soochow University, 199 Ren'ai Rd, Suzhou, Jiangsu 215123, China
| | - Jian Xiang
- WuXi AppTec (Suzhou) Co., Ltd., 1336 Wuzhong Avenue, Wuzhong District, Suzhou 215104, China
| | - Hairong Wang
- Children's Hospital of Soochow University, Suzhou, Jiangsu 215006, China
| | - Qi Zhuang
- Institute of Functional Nano & Soft Materials (FUNSOM), Soochow University, 199 Ren'ai Rd, Suzhou, Jiangsu 215123, China
- Jiangsu Key Laboratory for Carbon-Based Functional Materials and Devices, Soochow University, 199 Ren'ai Rd, Suzhou, Jiangsu 215123, China
| | - Ting Wei
- InnoBM Pharmaceuticals Co., Ltd., Suzhou, Jiangsu 215000, China
| | - Zhiqin Cao
- Institute of Functional Nano & Soft Materials (FUNSOM), Soochow University, 199 Ren'ai Rd, Suzhou, Jiangsu 215123, China
- Jiangsu Key Laboratory for Carbon-Based Functional Materials and Devices, Soochow University, 199 Ren'ai Rd, Suzhou, Jiangsu 215123, China
| | - Qingyang Gu
- WuXi AppTec (Suzhou) Co., Ltd., 1336 Wuzhong Avenue, Wuzhong District, Suzhou 215104, China
| | - Zhuang Liu
- Institute of Functional Nano & Soft Materials (FUNSOM), Soochow University, 199 Ren'ai Rd, Suzhou, Jiangsu 215123, China
- Jiangsu Key Laboratory for Carbon-Based Functional Materials and Devices, Soochow University, 199 Ren'ai Rd, Suzhou, Jiangsu 215123, China
| | - Rui Peng
- Institute of Functional Nano & Soft Materials (FUNSOM), Soochow University, 199 Ren'ai Rd, Suzhou, Jiangsu 215123, China
- Jiangsu Key Laboratory for Carbon-Based Functional Materials and Devices, Soochow University, 199 Ren'ai Rd, Suzhou, Jiangsu 215123, China
| |
Collapse
|
2
|
Bai MT, Li Y, Hu ZL. Ragweed pollen induces allergic conjunctivitis immune tolerance in mice via regulation of the NF-κB signal pathway. Int J Ophthalmol 2021; 14:955-964. [PMID: 34282378 DOI: 10.18240/ijo.2021.07.01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2020] [Accepted: 03/25/2021] [Indexed: 11/23/2022] Open
Abstract
AIM To investigate the feasibility and mechanism of immune tolerance in allergic conjunctivitis. METHODS The allergic conjunctivitis immune tolerance mice model was established by ragweed pollen (RW) and the related cytokines were detected. The mice were divided into 9 groups and the maslinic acid (MA) or PBS were given for different group after modeling. The expression levels of chemokine ligand 5 (CCL5) and P-65 in the conjunctival tissue were analyzed by immunohistochemistry, quantitative reverse transcription polymerase chain reaction (qRT-PCR) and Western blot. The percentage of interleukin-17 (IL-17) and CD4+CD25+ in the splenocyte supernatant was analyzed by flow cytometry. Furthermore, the serum and splenocyte supernatant concentration of total-IgE, interleukin-10 (IL-10), and IL-17 was analyzed by enzyme linked immune response (ELISA). RESULTS After the model was established, symptoms of conjunctivitis were alleviated, the level of P-65, CCL5, IL-17, and total-IgE was raised, while the expression of IL-10, CD4+CD25+ was decreased. This result fully demonstrated that a typical IL-17/regulatory-T-cells (Treg cells) imbalance and NF-κB activation. When the NF-κB signal pathway was suppressed, it showed that there was a further relief of conjunctivitis in mice. At the same time, the expression of total-IgE, IL-17, and CCL5 was decreased and the expression of anti-inflammatory factor (IL-10, CD4+CD25+) was increased. CONCLUSION In the state of immune tolerance, symptoms of conjunctivitis in mice are alleviated, the Th-17 cells of allergic conjunctivitis mice are inhibited, and Treg cells activity is enhanced.
Collapse
Affiliation(s)
- Meng-Tian Bai
- Department of Ophthalmology, Fourth Affiliated Hospital of Kunming Medical University, Kunming 650032, Yunnan Province, China.,Yunnan Eye Institute, Kunming 650032, Yunnan Province, China.,Key Laboratory of Yunnan Province for the Prevention and Treatment of Ophthalmology, Kunming 650032, Yunnan Province, China.,Provincial Innovation Team for Cataract and Ocular Fundus Disease, Fourth Affiliated Hospital of Kunming Medical University, Kunming 650032, Yunnan Province, China.,Expert Workstation of Yao Ke, Kunming 650032, Yunnan Province, China.,Department of Ophthalmology, Suining Central Hospital, Suining 629000, Sichuan Province, China
| | - Yun Li
- Department of Oncology, Suining Central Hospital, Suining 629000, Sichuan Province, China
| | - Zhu-Lin Hu
- Department of Ophthalmology, Fourth Affiliated Hospital of Kunming Medical University, Kunming 650032, Yunnan Province, China.,Yunnan Eye Institute, Kunming 650032, Yunnan Province, China.,Key Laboratory of Yunnan Province for the Prevention and Treatment of Ophthalmology, Kunming 650032, Yunnan Province, China.,Provincial Innovation Team for Cataract and Ocular Fundus Disease, Fourth Affiliated Hospital of Kunming Medical University, Kunming 650032, Yunnan Province, China.,Expert Workstation of Yao Ke, Kunming 650032, Yunnan Province, China
| |
Collapse
|